Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 114 participants.

Also called NCT06712030

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 114 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06712030
  • EU CT 2024-515661-34-00
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06712030. Randomized; single masking; primary purpose treatment. Start 2025-01 (anticipated); primary completion 2027-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction
Acronym
SAVA-TTR
Condition
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Intervention (Drug)
Sacubitril / Valsartan
Lead sponsor
Puerta de Hierro University Hospital (class: other)

Record details

Record id
cardio:ct-nct06712030
Content hash
3404440e025219c100f1aa6a5932ae33a8cc491c6b76c14f6c7b8cb6279955c4